Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Currency-adjusted sales revenue up 2.8%; order intake in constant currencies up 0.9%; operating result (EBITA) at EUR40.6 million; EBITA margin: 8.9%; financing on a solid, broad-based footing;

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

Figures for the First Nine Months of 2008


To ensure the best possible comparability, the figures of the year-earlier period are presented on a pro forma basis and adjusted for non-operating effects.

For the nine-month period, the Sartorius Group achieved a currency-adjusted gain of 2.8%. Consolidated sales revenue in the reporting currency is at EUR453.4 million (2007 pro forma: EUR458.8 mn; -1.2%). The Biotechnology Division's sales revenue was up a currency-adjusted 1.0%, but edged down 3.0% in the reporting currency, from EUR281.8 mn to EUR273.3 mn. The Mechatronics Division´s revenue grew 1.7% (currency-adjusted: +5.5%) from EUR177.0 mn to EUR180.0 mn. The Group´s order intake eased 3.0% (currency-adjusted: +0.9%) from EUR468.2 mn to EUR454.0 mn (Biotechnology: -5.1%, currency-adjusted: -1.1%; Mechatronics: +0.2%, currency-adjusted: +3.9%.

Operating earnings (EBITA) are at EUR40.6 million relative to EUR46.9 million a year ago (Biotechnology: EUR29.1 mn vs. EUR35.2 mn in 2007; Mechatronics: EUR11.4 mn vs. EUR11.7 mn in 2007). Currency effects and the higher R&D costs budgeted weighed down on earnings. Particularly impacted by the higher euro-zone base interest rate, consolidated net profit after minority interest totals EUR10.0 mn (2007: EUR16.2 mn). Earnings per share, excluding the two non-cash items of amortization and interest for the share price warrants granted, are accordingly at EUR0.80 (2007: EUR1.11).

In view of the increasingly difficult global economic conditions, we currently do not consider it possible to make an accurate and reliable quantitative forecast of further business development. We continue to see ourselves well-positioned in our markets, but do not expect to reach the full-year targets we announced on the basis of our first-half 2008 figures, because of the gloomy economic environment. However, we do anticipate a robust operating result for the fourth quarter as well.

in millions of EUR (unless      9-month 2008    9-month 2007    Change
otherwise specified)                            pro forma       in %

Sartorius Group
Sales revenue                   453.4           458.8           -1.2 (+2.8)
Order intake                    454.0           468.2           -3.0 (+0.9)
EBITA 1)                        40.6            46.9            -13.6
Net profit 1)2)                 13.7            18.9            -27.8
Earnings per share 1)2) in EUR  0.80            1.11

Biotechnology Division
Sales revenue                   273.3           281.8           -3.0 (+1.0)
Order intake                    269.3           283.8           -5.1 (-1.1)
EBITA 1)                        29.1            35.2            -17.2

Mechatronics Division
Sales revenue                   180.0           177.0           +1.7 (+5.5)
Order intake                    184.8           184.5           +0.2 (+3.9)
EBITA 1)                        11.4            11.7            -2.8 

in parentheses: currency-adjusted 1) For 2007 adjusted for non-operating effects 2) Excluding non-cash amortization and, for 2008, additionally excluding non-cash interest expenses for share price warrants

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the nine-month results for Sartorius with analysts and investors in a teleconference today (Oct. 28, 2008) at 3 p.m. CET. You may dial into this teleconference starting at 2:45 p.m. CET at the following numbers:

Germany:        +49 (0) 69 2222 2220;   France: +33 (0) 1 70 99 42 82;
UK:             +44 (0) 20 7138 0839;   USA:    +1 718 354 1362

The dial-in code is:    4944170. 

To view the webcast, log onto

end of announcement                               euro adhoc

Further inquiry note:

Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Original-Content von: Sartorius AG, übermittelt durch news aktuell

Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: